Exposure-adjusted yearly incidence rates for newly occurring arterial occlusive events and median dose intensity by year. (A) CP-CML patients. For CP-CML patients, in the 5 intervals shown (0 to <1 year, 1 to <2 years, 2 to <3 years, 3 to <4 years, and 4 to <5 years): 32, 21, 14, 8, and 3 patients had events, respectively, of 270, 152, 121, 91, and 73 patients in each interval, respectively. (B) All patients. For all patients, in the 5 intervals shown (0 to <1 year, 1 to <2 years, 2 to <3 years, 3 to <4 years, and 4 to <5 years): 47, 27, 15, 11, and 3 patients had events, respectively, of 449, 212, 158, 115, and 93 patients in each interval, respectively. Median follow-up was 56.8 months for CP-CML patients and 37.3 months for all patients.